研究二甲双胍和肌醇治疗多囊卵巢综合征的效果:一个研究方案

M. Aziz
{"title":"研究二甲双胍和肌醇治疗多囊卵巢综合征的效果:一个研究方案","authors":"M. Aziz","doi":"10.26685/urncst.473","DOIUrl":null,"url":null,"abstract":"Introduction: Polycystic Ovary Syndrome (PCOS), an androgen hormone excess and ovarian dysfunction disorder is linked to insulin resistance, metabolic disorders, and obesity. Inositol, a natural sugar compound is effective in regulating insulin levels and follicle stimulating hormones. Metformin, a biguanide drug which is used for Type 2 Diabetes treatment controls glucose levels and insulin resistance. Using inositol and metformin together for treatment of PCOS has been suggested to be beneficial for individuals with PCOS. The purpose of this study is to assess the effectiveness of metformin and inositol in improving insulin resistance, hyperandrogenism, weight, menstruation, and ovulation. Methods: A total of 36 women between ages of 25-35 clinically diagnosed with PCOS will be recruited to participate in a six-month double- blinded controlled trial. Participants were classified to normal BMI (18.5-24.0 kg/m2) and overweight/obese BMI (25.0-29.9 kg/m2 and >30 kg/m2) and were randomized into one of the following treatments: 500 mg of metformin with 4 g of inositol, 250 mg of metformin twice daily or two placebo sugar pills. Over the 6-month period, blood tests for blood sugar, insulin levels and testosterone levels, weight assessment on scale, menstruation questionnaire and ultrasound will be used to assess improvement in symptomology. Anticipated Results: It is anticipated that in both BMI groups, there will be a decrease in insulin resistance and hyperandrogenism with metformin and inositol use. There should be a reduction of weight in both BMI groups with increased effect seen in overweight/obese BMI. Menstruation and ovulation are anticipated to become more regular in both BMI groups using metformin and inositol. Discussion: Studies have found that metformin significantly improves insulin resistance, decrease circulating free androgens, and increases sex hormone binding globulin. Inositol has been seen to decrease insulin resistance, LH/FSH ratio and free androgen in women with PCOS. The combination of metformin and inositol is seen to improve hormonal and biochemical parameters and have a significant effect on menstrual cycle length. Conclusion: The combination of metformin and inositol may have synergistic effects that will PCOS symptomology and improve quality of life.","PeriodicalId":245521,"journal":{"name":"Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal","volume":"361 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Investigating the Effects of Metformin and Inositol in the Treatment of Polycystic Ovary Syndrome: A Research Protocol\",\"authors\":\"M. Aziz\",\"doi\":\"10.26685/urncst.473\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: Polycystic Ovary Syndrome (PCOS), an androgen hormone excess and ovarian dysfunction disorder is linked to insulin resistance, metabolic disorders, and obesity. Inositol, a natural sugar compound is effective in regulating insulin levels and follicle stimulating hormones. Metformin, a biguanide drug which is used for Type 2 Diabetes treatment controls glucose levels and insulin resistance. Using inositol and metformin together for treatment of PCOS has been suggested to be beneficial for individuals with PCOS. The purpose of this study is to assess the effectiveness of metformin and inositol in improving insulin resistance, hyperandrogenism, weight, menstruation, and ovulation. Methods: A total of 36 women between ages of 25-35 clinically diagnosed with PCOS will be recruited to participate in a six-month double- blinded controlled trial. Participants were classified to normal BMI (18.5-24.0 kg/m2) and overweight/obese BMI (25.0-29.9 kg/m2 and >30 kg/m2) and were randomized into one of the following treatments: 500 mg of metformin with 4 g of inositol, 250 mg of metformin twice daily or two placebo sugar pills. Over the 6-month period, blood tests for blood sugar, insulin levels and testosterone levels, weight assessment on scale, menstruation questionnaire and ultrasound will be used to assess improvement in symptomology. Anticipated Results: It is anticipated that in both BMI groups, there will be a decrease in insulin resistance and hyperandrogenism with metformin and inositol use. There should be a reduction of weight in both BMI groups with increased effect seen in overweight/obese BMI. Menstruation and ovulation are anticipated to become more regular in both BMI groups using metformin and inositol. Discussion: Studies have found that metformin significantly improves insulin resistance, decrease circulating free androgens, and increases sex hormone binding globulin. Inositol has been seen to decrease insulin resistance, LH/FSH ratio and free androgen in women with PCOS. The combination of metformin and inositol is seen to improve hormonal and biochemical parameters and have a significant effect on menstrual cycle length. Conclusion: The combination of metformin and inositol may have synergistic effects that will PCOS symptomology and improve quality of life.\",\"PeriodicalId\":245521,\"journal\":{\"name\":\"Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal\",\"volume\":\"361 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-08-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.26685/urncst.473\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26685/urncst.473","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

简介:多囊卵巢综合征(PCOS)是一种雄激素过量和卵巢功能障碍,与胰岛素抵抗、代谢紊乱和肥胖有关。肌醇是一种天然糖化合物,能有效调节胰岛素水平和促卵泡激素。二甲双胍是一种双胍类药物,用于治疗2型糖尿病,控制血糖水平和胰岛素抵抗。肌醇和二甲双胍联合治疗多囊卵巢综合征已被认为对多囊卵巢综合征患者有益。本研究的目的是评估二甲双胍和肌醇在改善胰岛素抵抗、高雄激素症、体重、月经和排卵方面的有效性。方法:招募36名年龄在25-35岁之间临床诊断为PCOS的女性参加为期6个月的双盲对照试验。参与者被分为正常BMI (18.5-24.0 kg/m2)和超重/肥胖BMI (25.0-29.9 kg/m2和bb0 - 30 kg/m2),并被随机分为以下治疗之一:500 mg二甲双胍加4 g肌醇,250 mg二甲双胍,每天两次或两次安慰剂糖丸。在6个月的时间里,将使用血糖、胰岛素水平和睾丸激素水平的血液测试、体重秤评估、月经问卷和超声波来评估症状的改善。预期结果:预计在两个BMI组中,使用二甲双胍和肌醇会减少胰岛素抵抗和高雄激素症。在两个BMI组中都应该有体重减轻的效果,超重/肥胖组的效果更明显。在使用二甲双胍和肌醇的BMI组中,月经和排卵预期会变得更加规律。讨论:研究发现,二甲双胍可显著改善胰岛素抵抗,降低循环游离雄激素,增加性激素结合球蛋白。肌醇可以降低多囊卵巢综合征女性的胰岛素抵抗、LH/FSH比值和游离雄激素。二甲双胍联合肌醇可改善激素和生化参数,并对月经周期长度有显著影响。结论:二甲双胍与肌醇联用可能具有协同作用,可改善PCOS患者的症状,改善生活质量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Investigating the Effects of Metformin and Inositol in the Treatment of Polycystic Ovary Syndrome: A Research Protocol
Introduction: Polycystic Ovary Syndrome (PCOS), an androgen hormone excess and ovarian dysfunction disorder is linked to insulin resistance, metabolic disorders, and obesity. Inositol, a natural sugar compound is effective in regulating insulin levels and follicle stimulating hormones. Metformin, a biguanide drug which is used for Type 2 Diabetes treatment controls glucose levels and insulin resistance. Using inositol and metformin together for treatment of PCOS has been suggested to be beneficial for individuals with PCOS. The purpose of this study is to assess the effectiveness of metformin and inositol in improving insulin resistance, hyperandrogenism, weight, menstruation, and ovulation. Methods: A total of 36 women between ages of 25-35 clinically diagnosed with PCOS will be recruited to participate in a six-month double- blinded controlled trial. Participants were classified to normal BMI (18.5-24.0 kg/m2) and overweight/obese BMI (25.0-29.9 kg/m2 and >30 kg/m2) and were randomized into one of the following treatments: 500 mg of metformin with 4 g of inositol, 250 mg of metformin twice daily or two placebo sugar pills. Over the 6-month period, blood tests for blood sugar, insulin levels and testosterone levels, weight assessment on scale, menstruation questionnaire and ultrasound will be used to assess improvement in symptomology. Anticipated Results: It is anticipated that in both BMI groups, there will be a decrease in insulin resistance and hyperandrogenism with metformin and inositol use. There should be a reduction of weight in both BMI groups with increased effect seen in overweight/obese BMI. Menstruation and ovulation are anticipated to become more regular in both BMI groups using metformin and inositol. Discussion: Studies have found that metformin significantly improves insulin resistance, decrease circulating free androgens, and increases sex hormone binding globulin. Inositol has been seen to decrease insulin resistance, LH/FSH ratio and free androgen in women with PCOS. The combination of metformin and inositol is seen to improve hormonal and biochemical parameters and have a significant effect on menstrual cycle length. Conclusion: The combination of metformin and inositol may have synergistic effects that will PCOS symptomology and improve quality of life.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.10
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信